EFG Asset Management North America Corp. Buys 27,192 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

EFG Asset Management North America Corp. increased its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 59.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 73,160 shares of the company’s stock after purchasing an additional 27,192 shares during the period. EFG Asset Management North America Corp.’s holdings in Vera Therapeutics were worth $3,092,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Victory Capital Management Inc. lifted its stake in shares of Vera Therapeutics by 13.5% in the third quarter. Victory Capital Management Inc. now owns 38,253 shares of the company’s stock worth $1,691,000 after buying an additional 4,546 shares in the last quarter. Intech Investment Management LLC purchased a new position in Vera Therapeutics in the 3rd quarter worth approximately $475,000. Charles Schwab Investment Management Inc. lifted its position in Vera Therapeutics by 3.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 361,805 shares of the company’s stock valued at $15,992,000 after acquiring an additional 10,717 shares in the last quarter. Algert Global LLC boosted its stake in Vera Therapeutics by 34.3% during the 3rd quarter. Algert Global LLC now owns 23,164 shares of the company’s stock valued at $1,024,000 after purchasing an additional 5,910 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Vera Therapeutics by 11.8% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 61,574 shares of the company’s stock worth $2,722,000 after purchasing an additional 6,494 shares in the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Price Performance

Shares of Vera Therapeutics stock opened at $27.15 on Tuesday. The stock has a market cap of $1.73 billion, a P/E ratio of -10.40 and a beta of 1.17. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The stock’s fifty day moving average is $31.50 and its 200 day moving average is $39.20. Vera Therapeutics, Inc. has a one year low of $25.99 and a one year high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.11. Sell-side analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Analyst Upgrades and Downgrades

VERA has been the topic of several recent analyst reports. Wolfe Research started coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They set an “outperform” rating and a $49.00 price objective on the stock. JPMorgan Chase & Co. dropped their price target on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a report on Tuesday, March 4th. The Goldman Sachs Group began coverage on shares of Vera Therapeutics in a research note on Tuesday, January 28th. They issued a “buy” rating and a $58.00 price target for the company. Finally, Guggenheim raised their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $64.67.

Insider Buying and Selling at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $41.74, for a total transaction of $730,450.00. Following the transaction, the chief executive officer now owns 143,603 shares in the company, valued at approximately $5,993,989.22. The trade was a 10.86 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 21.70% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.